| 101 |
24223823 | Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. | 2013 |
3 |
| 102 |
24367627 | OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis. | 2013 |
1 |
| 103 |
22002102 | p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737. | 2012 Feb |
1 |
| 104 |
22064351 | MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. | 2012 Apr |
3 |
| 105 |
22128299 | Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. | 2012 Jan 15 |
6 |
| 106 |
22173547 | Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. | 2012 Feb 1 |
3 |
| 107 |
22179721 | Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad. | 2012 Apr |
2 |
| 108 |
22311987 | Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. | 2012 Mar 23 |
3 |
| 109 |
22490358 | [The effect of cell killing by ABT-737 synergized with docetaxel in human prostate cancer PC-3 cells]. | 2012 Feb 1 |
1 |
| 110 |
22525702 | Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. | 2012 Jun 15 |
3 |
| 111 |
22609455 | Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. | 2012 Sep |
7 |
| 112 |
22814102 | S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak. | 2012 |
2 |
| 113 |
22875003 | Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. | 2012 Aug 9 |
1 |
| 114 |
22898329 | Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine. | 2012 Aug 16 |
4 |
| 115 |
22971477 | ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo. | 2012 |
2 |
| 116 |
23336025 | Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors. | 2012 Nov 1 |
3 |
| 117 |
21368833 | SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. | 2011 Mar 3 |
1 |
| 118 |
21393866 | Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. | 2011 Mar |
2 |
| 119 |
21555592 | Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. | 2011 May 24 |
1 |
| 120 |
21566062 | Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. | 2011 Jul |
5 |
| 121 |
21608150 | Mcl-1 ubiquitination and destruction. | 2011 Mar |
1 |
| 122 |
21628457 | Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. | 2011 Jul 15 |
1 |
| 123 |
21659544 | Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. | 2011 Aug 4 |
1 |
| 124 |
21664043 | GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. | 2011 Oct 1 |
2 |
| 125 |
21721047 | Molecular dynamics study of small molecule inhibitors of the Bcl-2 family. | 2011 Sep |
2 |
| 126 |
21772052 | An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. | 2011 Sep 29 |
2 |
| 127 |
21784061 | Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. | 2011 Nov 1 |
2 |
| 128 |
21821698 | ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. | 2011 Sep 15 |
5 |
| 129 |
21835956 | ABT-737 is highly effective against molecular subgroups of multiple myeloma. | 2011 Oct 6 |
2 |
| 130 |
20023629 | Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. | 2010 Jan 7 |
1 |
| 131 |
20159606 | DUB-le Trouble for Cell Survival. | 2010 Feb 17 |
1 |
| 132 |
20179162 | Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. | 2010 Mar |
1 |
| 133 |
20197552 | Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. | 2010 Apr 22 |
2 |
| 134 |
20515947 | ARC synergizes with ABT-737 to induce apoptosis in human cancer cells. | 2010 Jun |
1 |
| 135 |
20576107 | Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1. | 2010 Jun 24 |
1 |
| 136 |
20732961 | Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines. | 2010 Sep 1 |
3 |
| 137 |
20799354 | The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. | 2010 Oct |
3 |
| 138 |
20818182 | Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression. | 2010 Nov 1 |
3 |
| 139 |
20829195 | A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax). | 2010 Nov |
1 |
| 140 |
18987671 | BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. | 2009 Apr |
1 |
| 141 |
19008458 | Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. | 2009 Apr 30 |
1 |
| 142 |
19246337 | ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. | 2009 May |
2 |
| 143 |
19372561 | Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. | 2009 Apr |
1 |
| 144 |
19556859 | Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. | 2009 Aug |
1 |
| 145 |
19641525 | The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. | 2009 Nov |
1 |
| 146 |
19684859 | RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. | 2009 Aug 17 |
2 |
| 147 |
18028486 | ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. | 2008 Jan |
1 |
| 148 |
18398104 | Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. | 2008 Apr 16 |
9 |
| 149 |
18413764 | BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. | 2008 Apr 15 |
1 |
| 150 |
18599488 | ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. | 2008 Sep 5 |
1 |